Momenta is a biotechnology company with a validated innovative disease analytics platform. Our scientific foundation is a set of tools and methods that allow us to develop a deep understanding of the links between a compound’s chemical structure, biological function and its manufacturing process. We are applying our innovative technology to the discovery and development of novel therapeutics for immune-mediated diseases with high unmet need. Momenta also has a focused pipeline of two biosimilar candidates: M923, Momenta’s wholly-owned proposed biosimilar to HUMIRA®, and M710, a proposed biosimilar to EYLEA® being developed in collaboration with Mylan.
LOVENOX® is a registered trademark of Sanofi-Aventis. COPAXONE® is a registered trademark of Teva Pharmaceutical Industries Ltd. Glatopa® is a registered trademark of Novartis AG. Enoxaparin Sodium Injection and Glatopa™ were developed under a collaboration agreement between Momenta and Sandoz. Both products are marketed under the Sandoz brand.. EYLEA® (aflibercept) is a registered trademark of Regeneron Pharmaceuticals, Inc.
Last Updated 11/7/18